Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
暂无分享，去创建一个
J. Tanizaki | K. Nakagawa | Y. Chiba | K. Yonesaka | M. Takeda | J. Tsurutani | H. Hayashi | T. Tamura | H. Ueda | H. Kawakami | K. Haratani | Takeshi Yoshida | N. Takegawa | Satomi Watanabe | T. Takahama | Y. Nonagase | S. Watanabe | Yoshikane Nonagase